These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 9465680)

  • 1. [The prevention of cytomegalovirus infection and disease by administration of biological products].
    Ihara T
    Nihon Rinsho; 1998 Jan; 56(1):145-50. PubMed ID: 9465680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytomegalovirus infection in transplant recipients].
    Gondo H
    Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus vaccines: current status.
    Starr SE
    Infect Agents Dis; 1992 Jun; 1(3):146-8. PubMed ID: 1365538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients.
    Plotkin SA; Higgins R; Kurtz JB; Morris PJ; Campbell DA; Shope TC; Spector SA; Dankner WM
    Transplantation; 1994 Dec; 58(11):1176-8. PubMed ID: 7992358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines for the prevention of human cytomegalovirus infection.
    Plotkin SA; Starr SE; Friedman HM; Gonczol E; Brayman K
    Rev Infect Dis; 1990; 12 Suppl 7():S827-38. PubMed ID: 2173112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
    Torres-Madriz G; Boucher HW
    Clin Infect Dis; 2008 Sep; 47(5):702-11. PubMed ID: 18652557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The status of cytomegalovirus vaccine.
    Starr SE; Friedman HM; Plotkin SA
    Rev Infect Dis; 1991; 13 Suppl 11():S964-5. PubMed ID: 1664136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective reconstitution of CD8+ cytotoxic T lymphocyte responses in immunodeficient bone marrow transplant recipients by the adoptive transfer of T cell clones.
    Riddell SR; Walter BA; Gilbert MJ; Greenberg PD
    Bone Marrow Transplant; 1994; 14 Suppl 4():S78-84. PubMed ID: 7728132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients.
    Roman A; Manito N; Campistol JM; Cuervas-Mons V; Almenar L; Arias M; Casafont F; del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Serón D; Ussetti P;
    Transplant Rev (Orlando); 2014 Apr; 28(2):84-91. PubMed ID: 24602805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant.
    Bowden RA; Slichter SJ; Sayers M; Weisdorf D; Cays M; Schoch G; Banaji M; Haake R; Welk K; Fisher L; McCullough J; Miller W
    Blood; 1995 Nov; 86(9):3598-603. PubMed ID: 7579469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Importance of screening for antibodies to cytomegalovirus in organ transplantation].
    Milbradt H; Flik J; Stangel W; Heigel R
    Beitr Infusionsther; 1990; 26():33-6. PubMed ID: 1703866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial.
    Plotkin SA; Starr SE; Friedman HM; Brayman K; Harris S; Jackson S; Tustin NB; Grossman R; Dafoe D; Barker C
    Ann Intern Med; 1991 Apr; 114(7):525-31. PubMed ID: 1848053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experiences with transfusion of CMV tested blood preparations after bone marrow transplantation].
    Luboldt W; Henneberg-Quester KB; Schaefer UW; Beelen DW; Quabeck K; Thraenhart O
    Beitr Infusionsther; 1990; 26():190-3. PubMed ID: 1703827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients.
    Winston DJ; Ho WG; Bartoni K; Champlin RE
    Bone Marrow Transplant; 1993 Sep; 12(3):283-8. PubMed ID: 8241988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients.
    Riddell SR; Reusser P; Greenberg PD
    Rev Infect Dis; 1991; 13 Suppl 11():S966-73. PubMed ID: 1664137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoprophylaxis against cytomegalovirus disease.
    Adler SP
    Scand J Infect Dis Suppl; 1995; 99():105-9. PubMed ID: 8668931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus infection in organ transplant recipients.
    Hibberd PL; Snydman DR
    Infect Dis Clin North Am; 1995 Dec; 9(4):863-77. PubMed ID: 8747770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress on human cytomegalovirus vaccines for prevention of congenital infection and disease.
    Wang D; Fu TM
    Curr Opin Virol; 2014 Jun; 6():13-23. PubMed ID: 24632198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.